…
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on eXoZymes, Inc. is limited; the company is a Nasdaq-listed life sciences firm that appears focused on enzyme-based technologies and related therapeutics. Long-term growth may be driven by clinical or product development milestones, strategic partnerships, and successful commercialization if pipelines advance. Investors may find exposure to enzyme-focused biotech innovation coupled with potential upside from milestone achievements.
Material risks include development and regulatory uncertainty, likely limited revenue and the need for additional financing, and strong competition in the biotech sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -9.26M | -5.86M | -2.00M | -1.33M | -1.21M |
| Net income | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
| Selling general administrative | 5.91M | 4.06M | 1.34M | 0.98M | 0.84M |
| Gross profit | - | -0.27M | - | -0.15M | -0.06M |
| Reconciled depreciation | 0.29M | 0.27M | 0.20M | 0.15M | 0.06M |
| Ebit | -9.72M | -5.86M | -1.80M | -1.33M | -1.21M |
| Ebitda | -9.43M | -5.59M | -1.60M | -1.18M | -1.15M |
| Depreciation and amortization | 0.29M | 0.27M | 0.20M | 0.15M | 0.06M |
| Operating income | -9.72M | -5.93M | -1.80M | -1.33M | -1.29M |
| Other operating expenses | 9.72M | 5.93M | 1.80M | 1.33M | 1.29M |
| Tax provision | -0.11M | 0.00M | 0.04M | 0.06M | 0.00M |
| Interest income | - | - | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.36M | 0.08M | 0.00M | 0.00M | 0.00M |
| Income tax expense | -0.11M | - | 0.04M | 0.06M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 9.72M | 5.66M | 1.80M | 1.18M | 1.23M |
| Cost of revenue | - | 0.27M | - | 0.15M | 0.06M |
| Total other income expense net | 0.45M | 0.07M | -0.20M | 0.00M | 0.08M |
| Net income from continuing ops | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Other current assets | 0.38M | 0.36M | 0.26M | 0.10M | 0.03M |
| Total liab | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Total stockholder equity | 3.40M | 10.42M | -0.38M | 1.37M | 1.20M |
| Other current liab | 0.01M | 0.18M | 1.45M | 0.04M | -0.13M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -21.10M | -11.95M | -6.08M | -4.05M | -2.65M |
| Cash | 3.04M | 9.72M | 0.07M | 0.56M | 0.55M |
| Total current liabilities | 1.57M | 1.33M | 2.42M | 0.63M | 0.40M |
| Net debt | -1.80M | -8.33M | 1.55M | 0.05M | 0.17M |
| Short term debt | 0.33M | 0.23M | 0.22M | 0.15M | 0.13M |
| Short long term debt total | 1.24M | 1.39M | 1.61M | 0.61M | 0.72M |
| Other stockholder equity | 24.50M | 22.37M | 5.70M | 5.42M | 3.85M |
| Total current assets | 3.94M | 10.82M | 1.21M | 1.47M | 1.05M |
| Net receivables | 0.52M | 0.74M | 0.88M | 0.81M | 0.47M |
| Accounts payable | 1.24M | 0.92M | 0.70M | 0.39M | 0.27M |
| Non currrent assets other | -0.18M | - | - | - | - |
| Non current assets total | 2.03M | 2.21M | 2.34M | 1.22M | 1.30M |
| Capital lease obligations | 1.24M | 1.39M | 1.61M | 0.61M | 0.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.36M | -0.31M | -0.09M | -0.31M |
| Total cashflows from investing activities | -0.15M | -0.36M | -0.31M | -0.09M | -0.31M |
| Net borrowings | -0.03M | 0.00M | - | - | - |
| Total cash from financing activities | -0.03M | 18.52M | 1.00M | 1.36M | 2.31M |
| Net income | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
| Change in cash | -6.68M | 9.65M | -0.49M | 0.01M | 0.41M |
| Begin period cash flow | 9.72M | 0.07M | 0.56M | 0.55M | 0.13M |
| End period cash flow | 3.04M | 9.72M | 0.07M | 0.56M | 0.55M |
| Total cash from operating activities | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Issuance of capital stock | 0.00M | 14.53M | 0.00M | 1.36M | 2.31M |
| Depreciation | -0.05M | 0.27M | 0.20M | 0.15M | 0.06M |
| Other cashflows from investing activities | 0.02M | 0.04M | -0.02M | 0.10M | 0.11M |
| Change to account receivables | 0.11M | 0.15M | -0.07M | -0.34M | -0.32M |
| Other cashflows from financing activities | -0.03M | 0.01M | 1.00M | - | - |
| Capital expenditures | 0.17M | 0.40M | 0.29M | 0.19M | 0.42M |
| Change in working capital | 0.38M | -4.02M | 0.22M | -0.19M | -0.54M |
| Stock based compensation | 1.99M | 1.13M | 0.28M | 0.22M | 0.20M |
| Other non cash items | 0.34M | -0.02M | 0.16M | -0.04M | -0.10M |
| Free cash flow | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| EXOZ eXoZymes, Inc. |
-0.05 1.46% |
3.38 | - | - | - | 15.95 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 |
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Heltzen | President & CEO | 1981 |
| Dr. Tyler Korman Ph.D. | Co-Founder & Chief Scientific Officer | 1979 |
| Dr. Paul Opgenorth Ph.D. | Co-Founder & Vice President of Development | 1983 |
| Mr. James U. Bowie Ph.D. | Founder & Independent Director | 1962 |
| Mr. Fouad Nawaz | Vice President of Finance | 1986 |
| Mr. Damien A. Perriman | Chief Commercial Officer | 1977 |
| Mr. Lasse H. Gorlitz | Vice President of Communications | NA |
| Mr. Michael Burns | Executive Vice President of Energy Transition | NA |
| Ms. Amy Lunzer | Chief of Staff | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.